# InSightec clinical trials: 84 on ClinicalTrials.gov (2026)

Updated November 19, 2026.

ClinicalTrials.gov lists 84 trials with InSightec as lead sponsor, 9 of them recruiting or not yet recruiting, as read on November 19, 2026.

## The full list

Clinical trials led by InSightec: 84 rows for $5, every trial on ClinicalTrials.gov as read on November 19, 2026. Columns: NCT ID, Title, Sponsor, Sponsor class, Phase, Status, Conditions, Condition groups (MeSH), Interventions, Start date, First posted, Last update posted, Enrollment, Location countries, Read on, Source. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (sponsor class, condition groups (MeSH), interventions, start date, last update posted and location countries), which open on your screen as soon as the payment clears and come by email. The rows on this page are a sample.

Buy: https://specstream.ai/data/clinical-trials/company/insightec

SpecStream is the live web data engine for teams and agents. It reads ClinicalTrials.gov each morning, and this page is that reading. Ask for the sponsors, conditions, phases or places you follow and each new or changed trial arrives in your sheet, CRM, Slack or agent with the sponsor, phase, status and sites.

- Trials: 84
- Recruiting or not yet: 9
- Read on: November 19, 2026

## Trials

The 25 newest of 84, each linked to its ClinicalTrials.gov record. The full list holds every one.

| First posted | NCT ID | Title | Sponsor | Phase | Status | Conditions | Enrollment | Source |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| August 14, 2026 | NCT07764874 | Unilateral and Staged Bilateral Pallidothalamic Tractotomy Using Exablate MRgFUS in Advanced Parkinson's Disease. | InSightec | Not applicable | Not yet recruiting | Parkinson Disease | 120 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07764874) |
| May 16, 2025 | NCT06974916 | EMBRACE Tremor BiFUS | InSightec | Not applicable | Recruiting | Essential Tremor | 100 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06974916) |
| September 4, 2024 | NCT06584383 | A Prospective, Randomized, Controlled Trial to Test Safety and Effectiveness of Unilateral Exablate MR-guided Focused Ultrasound... | InSightec | Not applicable | Active not recruiting | Parkinson Disease | 67 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06584383) |
| November 29, 2022 | NCT05630209 | Blood Brain Barrier (BBB) Disruption Using Exablate Focused Ultrasound With Doxorubicin for Treatment of Pediatric Diffuse Intrinsic... | InSightec | Phase 1/2 | Active not recruiting | Brain Tumor | 10 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05630209) |
| November 14, 2022 | NCT05615623 | Blood Brain Barrier (BBB) Disruption Using Exablate Focused Ultrasound With Doxorubicin for Treatment of Pediatric DIPG | InSightec | Phase 1/2 | Active not recruiting | Brain Tumor | 10 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05615623) |
| October 4, 2022 | NCT05565443 | MR-guided Focused Ultrasound Plus GCase | InSightec | Not applicable | Active not recruiting | Parkinsons Disease | 14 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05565443) |
| September 14, 2022 | NCT05539196 | A Post-Approval Registry for Exablate 4000 Type 1.0 and Type 1.1 for Unilateral Pallidotomy for the Treatment of Advanced, Idiopathic... | InSightec | Observational | Recruiting | Movement Disorders, Neurology, Parkinsons Disease | 60 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05539196) |
| May 23, 2022 | NCT05386615 | Post-Exablate Pregnancy Outcomes Registry Study: Exablate Treatment of Symptomatic Uterine Fibroids | InSightec | Observational | Recruiting | Uterine Fibroid | 200 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05386615) |
| May 20, 2022 | NCT05383872 | Blood-Brain Barrier Disruption (BBBD) for Liquid Biopsy in Subjects With GlioBlastoma Brain Tumors | InSightec | Not applicable | Completed | Glioblastoma, Glioma, Liquid Biopsy | 71 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05383872) |
| April 8, 2022 | NCT05317858 | Blood-brain Barrier (BBB) Opening Using Exablate Focused Ultrasound With Standard of Care Treatment of NSCLC Brain Mets | InSightec | Phase 3 | Recruiting | Brain Tumor, Non Small Cell Lung Cancer | 96 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05317858) |
| October 22, 2021 | NCT05089786 | Echo-Focusing in Patients With Treatment-Resistant Neurologic and Psychiatric Indications (EF001) | InSightec | Not applicable | Withdrawn | Essential Tremor, Neurology | 0 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05089786) |
| August 10, 2021 | NCT04998864 | Assessment of Safety and Feasibility of ExAblate Blood-Brain Barrier (BBB) Disruption in GBM Patients | InSightec | Observational | Completed | Glioma, Malignant, Glioblastoma | 3 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04998864) |
| August 5, 2021 | NCT04991831 | A Post-Approval Registry for Exablate 4000 Type 1.0 and Type 1.1 for Unilateral Thalamotomy for the Treatment of Medication-Refractory... | InSightec | Observational | Recruiting | Tremor Associated With Tremor Dominant Parkinson's Disease | 50 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04991831) |
| February 9, 2021 | NCT04744493 | A Clinical Trial for the Safety and Effect of MRGuided FUS Subthalamotomy for Medication Refractory Parkinson's Disease | InSightec | Not applicable | Completed | Parkinson Disease | 10 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04744493) |
| January 28, 2021 | NCT04728295 | Evaluation of the Safety and Effectiveness of Bilateral Exablate Ablation of the Pallidothalamic Tract (PTT) for the Treatment of the Motor... | InSightec | Not applicable | Active not recruiting | Parkinson Disease | 50 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04728295) |
| December 16, 2020 | NCT04667715 | Safety and Effectiveness of Blood-Brain Barrier Disruption (BBBD) in Subjects With Suspected Infiltrating Glioma | InSightec | Not applicable | Withdrawn | Glioma | 0 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04667715) |
| December 2, 2020 | NCT04649554 | Study of MRgFUS Exablate Treatment Following the Neuropathic Pain | InSightec | Not applicable | Terminated | Neuropathic Pain | 2 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04649554) |
| June 19, 2020 | NCT04440358 | Exablate Blood-Brain Barrier Disruption With Carboplatin for the Treatment of rGBM | InSightec | Phase 1/2 | Completed | Recurrent Glioblastoma | 13 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04440358) |
| June 4, 2020 | NCT04417088 | Exablate Blood-Brain Barrier Disruption for the Treatment of rGBM in Subjects Undergoing Carboplatin Monotherapy | InSightec | Phase 1/2 | Completed | Recurrent Glioblastoma | 28 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04417088) |
| May 1, 2020 | NCT04370665 | Blood-Brain-Barrier Disruption With Cerezyme in Patient's With Parkinson's Disease | InSightec | Not applicable | Completed | Parkinson Disease | 4 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04370665) |
| December 13, 2019 | NCT04197921 | Exablate for LIFU Neuromodulation in Patients With Opioid Use Disorder (OUD) and/or Other Substance Use Disorders (SUDs) | InSightec | Not applicable | Recruiting | Opioid-use Disorder, Substance Use Disorders | 29 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04197921) |
| October 2, 2019 | NCT04112381 | Bilateral Treatment of Medication Refractory Essential Tremor | InSightec | Not applicable | Active not recruiting | Essential Tremor | 51 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04112381) |
| June 28, 2019 | NCT04002596 | Safety and Initial Effectiveness of Transcranial MR Guided Focused Ultrasound for the Treatment of Parkinson's Disease | InSightec | Not applicable | Completed | Parkinson Disease | 26 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04002596) |
| June 26, 2019 | NCT03998657 | Continued Access of Focal MR-Guided Focused Ultrasound for Localized Intermediate Risk Prostate Lesions | InSightec | Not applicable | Active not recruiting | Prostate Cancer | 14 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03998657) |
| May 28, 2019 | NCT03964272 | A Feasibility Study on the Safety and Preliminary Efficacy of Bilateral Subthalamotomy Using MRgFUS for Treatment of PD | InSightec | Not applicable | Completed | Parkinson Disease, Neurologic Manifestations | 6 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03964272) |

## By phase

| Phase | Trials |
| --- | --- |
| Phase 1 | 4 |
| Phase 1/2 | 4 |
| Phase 2 | 4 |
| Phase 3 | 4 |
| Not applicable | 62 |
| Observational | 6 |

## By status

| Status | Trials |
| --- | --- |
| Completed | 50 |
| Active not recruiting | 12 |
| Recruiting | 8 |
| Terminated | 7 |
| Withdrawn | 3 |
| Unknown | 2 |
| Suspended | 1 |
| Not yet recruiting | 1 |

## Conditions

| Condition group | Trials |
| --- | --- |
| Parkinson Disease | 17 |
| Essential Tremor | 13 |
| Prostatic Neoplasms | 10 |
| Leiomyoma | 10 |
| Breast Neoplasms | 9 |
| Glioblastoma | 8 |
| Brain Neoplasms | 7 |
| Glioma | 6 |
| Bone Neoplasms | 6 |
| Lung Neoplasms | 5 |
| Neoplasms | 5 |
| Neoplasm Metastasis | 4 |
| Cancer Pain | 4 |
| Pain | 4 |
| Tremor | 3 |
| Alzheimer Disease | 3 |
| Movement Disorders | 3 |
| Neurologic Manifestations | 2 |
| Neuralgia | 2 |
| Hemorrhage | 2 |
| Myofibroma | 2 |
| Trigeminal Neuralgia | 1 |
| Pelvic Pain | 1 |
| Amyotrophic Lateral Sclerosis | 1 |
| Epilepsy | 1 |

## Where the register publishes

- [ClinicalTrials.gov](https://clinicaltrials.gov/)
- [ClinicalTrials.gov API](https://clinicaltrials.gov/data-api/api)

Source: [ClinicalTrials.gov API v2 (U.S. National Library of Medicine)](https://clinicaltrials.gov/data-api/api). U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Recruiting means the record's overall status is recruiting or not yet recruiting. Condition groups are the MeSH terms ClinicalTrials.gov assigns; a condition page also counts the narrower terms that name it, as the register's own search does (triple negative breast neoplasms are breast neoplasms). Sites are shown as organizations only; no investigator or contact is read or shown.

Free to quote with credit and a link. Copying in bulk needs a [data licence](https://specstream.ai/data/licence).

## Business lists in the United States

- [Payroll companies in the United States](https://specstream.ai/data/businesses/payroll-companies/united-states)
- [Import and export companies in the United States](https://specstream.ai/data/businesses/import-and-export-companies/united-states)
- [DUI law firms in the United States](https://specstream.ai/data/businesses/dui-law-firms/united-states)
- [Bags luggage companies in the United States](https://specstream.ai/data/businesses/bags-luggage-companies/united-states)
- [Tractor dealers in the United States](https://specstream.ai/data/businesses/tractor-dealers/united-states)
- [Plumbers in the United States](https://specstream.ai/data/businesses/plumbers/united-states)
